Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr

The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022

Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr

The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022

Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr

The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility

Cheplapharm selects Generis’ CARA Life Sciences platform to unify their clinical processes

Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes

HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22

The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management

Dabur India expects low to mid-single digit revenue growth for Q3 FY23

International Business is expected to post double-digit revenue growth during the quarter in constant currency.

Ministry of Ayush and DST sign MoU to identify areas of research

The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products

Vivimed Labs Q2 FY2023 consolidated loss at Rs. 22.03 Cr

The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%